Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study).


Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
02 2020
Historique:
received: 04 06 2019
revised: 18 09 2019
accepted: 12 10 2019
pubmed: 24 11 2019
medline: 16 2 2021
entrez: 24 11 2019
Statut: ppublish

Résumé

To predict the 3-months mortality in permanently bedridden medical non-oncologic inpatients. 2788 consecutive patients admitted in 5 Italian Internal Medicine units from January 2016 through January 2017 were prospectively screened; 644 oncologic patients were excluded; 2144 non-oncologic patients (1021 female) were followed-up for mortality for 6 months. Main outcome was 3-months mortality in permanently bedridden inpatients with at least 2 of: creatinine clearance <35 ml/min; albumin < 2.5 g/dl; at least 2 hospital admissions in the previous 6 months. Advanced dementia and dysphagia were also recorded. Mean age of the 2144 patients was 73.9 (SD, 14.9) years; 374 (17%) were permanently bedridden, 435 (20%) had a creatinine clearance <35 ml/min, 217 (10%) albumin <2,5 g/dl, 112 (5%) at least 2 hospital admissions in the previous 6 months. Seventy-seven (4%) patients were permanently bedridden with at least 2 of the above mentioned items, and 48 of them died within 3 months (62%) (p < 0.001;95% CI 51-73%). Regression coefficients of the variables associated with 3-months mortality in multivariate analysis in 998 patients of unit 1 (training cohort) were used to create a simple score, which was validated in the 1146 patients of the other units (validation cohort) and performed well in predicting the 3-months mortality (https://www.ejcrim.com/beclap/). Approximately two out of three non-oncologic medical patients permanently bedridden having 2 of the abovementioned items are dead 3 months after index admission; a simple score including bedridden status, creatinine clearance, albumin, dysphagia, age and sex may help discuss management priorities.

Identifiants

pubmed: 31757579
pii: S0953-6205(19)30355-3
doi: 10.1016/j.ejim.2019.10.016
pii:
doi:

Substances chimiques

Albumins 0
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

60-66

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Antonio Brucato (A)

Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi d Milano, Ospedale Fatebenefratelli, Italy; Ospedale Papa Giovanni XXIII, Bergamo, Italy. Electronic address: antonio.brucato@unimi.it.

Alberto Ferrari (A)

Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address: aferrari@fondazionefrom.it.

Mara Tiraboschi (M)

Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi d Milano, Ospedale Fatebenefratelli, Italy.

Alberto Zucchi (A)

Epidemiology Unit, Health Protection Agency, Bergamo, Italy.

Chiara Cogliati (C)

Internal Medicine Department, L. Sacco Hospital, ASST fbf-sacco, Milan, Italy.

Daniela Torzillo (D)

Internal Medicine Department, L. Sacco Hospital, ASST fbf-sacco, Milan, Italy.

Francesco Dentali (F)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Luca Tavecchia (L)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Vera Gessi (V)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Alessandro Squizzato (A)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Sara Moretti (S)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Eleonora Tamborini Permunian (ET)

Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Alessandra Carobbio (A)

Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Luca Pasina (L)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.

Fabio De Stefano (F)

Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi d Milano, Ospedale Fatebenefratelli, Italy.

Enrico Tombetti (E)

Ospedale Papa Giovanni XXIII, Bergamo, Italy.

Davide Cumetti (D)

Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi d Milano, Ospedale Fatebenefratelli, Italy.

Gianni Tognoni (G)

Dipartimento di Anestesia-Rianimazione e Emergenza Urgenza, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Tiziano Barbui (T)

Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address: tbarbui@asst-pg23.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH